21 December 2017 - - San Francisco, California-based biotechnology company DiCE Molecules SV, LLC has formed a multi-year collaboration to discover new small molecules against multiple targets of interest to South San Francisco, California-based biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the company said.
The collaboration will build upon DiCE's technology platform, which leverages the power of directed chemical evolution to select and optimize low molecular weight compounds against pharmaceutical targets, such as protein-protein interfaces.
Under the terms of the agreement, DiCE will receive an undisclosed upfront payment and is eligible to receive research, development, regulatory, and commercial milestone payments based upon achievement of certain pre-determined milestones.
Full financial terms have not been disclosed.
Privately held DiCE is focused on the development of small molecule compounds that unlock previously intractable targets.
The company is focused on leveraging its capabilities to create a self-financing business generating returns for its shareholders through the achievement of milestones and revenues secured by collaborations while advancing its internal drug discovery efforts.
Genentech discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.